Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines

TÜRK TÜRK S., Malkan Ü. Y., Ghasemi M., Hocaoglu H., Mutlu D., Gunes G., ...More

SAGE OPEN MEDICINE, vol.5, 2017 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2017
  • Doi Number: 10.1177/2050312116689519
  • Journal Name: SAGE OPEN MEDICINE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Keywords: Ankaferd hemostat, anticancer, melanoma, MEDICINAL-PLANT EXTRACT, CONTROLLED CLINICAL-TRIAL, PARTIAL NEPHRECTOMY MODEL, RENAL TUBULAR APOPTOSIS, BLOOD STOPPER, IN-VITRO, PULPOTOMY, AGENTS, ABS
  • Hacettepe University Affiliated: Yes

Abstract

Objective: Ankaferd hemostat is the first topical hemostatic agent about the red blood cell-fibrinogen relations tested in the clinical trials. Ankaferd hemostat consists of standardized plant extracts including Alpinia) officinarum, Glycyrrhiza glabra, Thymus vulgaris, Urtica dioica, and Vitis vinifera. The aim of this study was to determine the effect of Ankaferd hemostat on viability of melanoma cell lines.